Phase 2 Study to Evaluate Dose Optimization and Anti-tumor Activity of Atebimetinib in Participants With Advanced or Metastatic NSCLC.
A Phase 2, Open-Label, Multicenter, Dose Optimization and Anti-Tumor Activity Study of Atebimetinib, a Novel Oral Dual MEK1/2 Inhibitor in Combinations With Cemiplimab and Chemotherapy in First Line, RAS-mutated, Locally Advanced or Metastatic NSCLC Participants
Atebimetinib Plus Cemiplimab, With or Without Chemotherapy, in First-Line RAS-Mutated Non-Small Cell Lung Cancer
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: IMM1104-201 Study Team
- Telefonnummer: (860) 321-1302
- E-mail: clinicaltrials@immuneering.com
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Aged 18 years or older
- Nnon-squamous NSCLC, stage IIIB or stage IV, with no prior systemic treatment for recurrent or metastatic disease. Prior adjuvant or neoadjuvant platinum therapy is allowed if completed more than 6 months before recurrence.
- Measurable disease (at least 1 target lesion) per RECIST 1.1.
- ECOG performance status of 0 or 1.
- PD-L1 score determined by an FDA-approved test.
- RAS-mutated NSCLC documented by next-generation sequencing (NGS), performed locally per institutional standards. Results must be available before enrollment. Liquid biopsy is acceptable.
- Adequate organ function:
Exclusion Criteria:
- Inability to swallow oral medications.
- EGFR, ALK or ROS1 mutation.
- Untreated or unresolved brain metastases
- Encephalitis, meningitis or uncontrolled seizures in the year before informed consent.
- History of interstitial lung disease non-infectious pneumonitis that required immunosuppressive doses of glucocorticoids, or any pneumonitis within the last 5 years. Radiation pneumonitis in the radiation field is permitted.
- Active autoimmune disease that required systemic treatment in the past 12 months.
- A condition requiring corticosteroids >10 mg/day prednisone or equivalent within 14 days of Cycle 1 Day 1.
- Prior allogeneic tissue or solid organ transplant.
- Never-smoker (fewer than 100 cigarettes in a lifetime).
- Prior anti-PD-1 or anti-PD-L1 therapy.
- Impaired cardiac function or clinically significant cardiac disease, including left ventricular ejection fraction <50% by ECHO or MUGA or screening QTcF >470 msec.
- History of serous retinopathy, retinal edema or retinal pigment epithelial detachment.
- History or current evidence of retinal vein occlusion (RVO), or current RVO risk factors.
- Rhabdomyolysis within 3 months before Study Day 1.
- Major surgery or significant traumatic injury within 4 weeks before the first dose.
- Another malignancy.
- Any infection requiring hospitalization or IV anti-infectives within 2 weeks before the first dose.
- Uncontrolled HIV, hepatitis B or hepatitis C infection; immunodeficiency; or active or latent tuberculosis.
- Live vaccine within 4 weeks before the first dose.
- COVID-19 vaccination within 1 week before the planned first dose, or a planned COVID-19 vaccination series that won't be completed at least 1 week before the first dose.
- Known hypersensitivity to any study drug or excipient.
- Unwillingness to use effective contraception
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Atebimetinib + Cemiplimab ± Chemotherapy
Participants receive atebimetinib orally once daily (160, 240 or 320 mg) plus cemiplimab 350 mg IV every 3 weeks. Carboplatin and pemetrexed are given IV every 3 weeks for 4 cycles in the dose optimization portion, and in the expansion portion for participants with PD-L1 <50%. The expansion uses the atebimetinib dose selected during dose optimization. |
Oral dual MEK1/2 inhibitor, immediate-release tablets, given once daily continuously at 160, 240 or 320 mg
Andre navne:
Anti-PD-1 monoclonal antibody, 350 mg IV every 3 weeks
Andre navne:
AUC 5 or 6 mg/mL/min IV (Calvert formula) on Day 1 of Cycles 1-4 500 mg/m² IV on Day 1 of Cycles 1-4
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Maximum Plasma Concentration (Cmax), Time to Maximum Plasma Concentration (Tmax) and Area under the curve (AUC0-t) of Atebimetinib
Tidsramme: Cycle 1 Day 1 Cycle 2 Day 1 Each cycle is 21 days.
|
Measured in dose optimization |
Cycle 1 Day 1 Cycle 2 Day 1 Each cycle is 21 days.
|
|
Objective Response Rate (ORR)
Tidsramme: Every 8 weeks, up to approximately 24 months
|
Percentage of participants with complete or partial response per RECIST 1.1 |
Every 8 weeks, up to approximately 24 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Median Progression-Free Survival (PFS)
Tidsramme: Up to approximately 24 months.
|
Time from Cycle 1 Day 1 to first documented disease progression per RECIST v1.1 or death from any cause, whichever comes first. |
Up to approximately 24 months.
|
|
Overall Survival (OS)
Tidsramme: From Cycle 1 Day 1 (each cycle is 21 days) until death from any cause, assessed every 12 weeks after treatment ends. Up to approximately 36 months.
|
Time from Cycle 1 Day 1 to death from any cause. |
From Cycle 1 Day 1 (each cycle is 21 days) until death from any cause, assessed every 12 weeks after treatment ends. Up to approximately 36 months.
|
|
Number of Participants with adverse events
Tidsramme: From first dose on Cycle 1 Day 1 through 90 days after the last dose. Each cycle is 21 days.
|
Treatment-emergent and treatment-related AEs per CTCAE v6.0 |
From first dose on Cycle 1 Day 1 through 90 days after the last dose. Each cycle is 21 days.
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Vinny Hayreh, Immuneering Corporation
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Neoplasmer efter sted
- Neoplasmer
- Luftvejssygdomme
- Lungesygdomme
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Karcinom, bronkogent
- Bronkiale neoplasmer
- Lungeneoplasmer
- Karcinom, ikke-småcellet lunge
- Aminosyrer, peptider og proteiner
- Organiske kemikalier
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Koordinationskomplekser
- Guanine
- Hypoxanthines
- Purinoner
- Puriner
- Glutamater
- Aminosyrer, sur
- Aminosyrer
- Aminosyrer, dicarboxylic
- Pemetrexed
- Carboplatin
- cemiplimab
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- IMM1104-201
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .